I often write about fatty liver disease, a problem that is gaining mainstream recognition as published earlier this year in Newsweek. It is easy to assume that this is a...
Read More
Galectin Therapeutics is focused on a treatment for advanced fatty liver disease, or NASH (non-alcoholic steatohepatitis), which includes those patients with advanced scarring, or who are at the end stage...
Read More
By Peter G. Traber, M.D. on April 21, 2016 I suppose it’s natural to assume that only overweight people get fatty liver disease (and NASH), but one thing I have...
Read More
By Peter G. Traber, M.D. on February 3, 2016 Are you one of the nearly 40% of Americans classified as obese or are you overweight and inexorably headed towards obesity? ...
Read More
By Peter G. Traber, M.D. on December 7, 2015 In June 2015 Galectin Therapeutics initiated a clinical trial to determine if our investigational drug GR-MD-02 can successfully treat patients with...
Read More
Written by Peter G. Traber, M.D. on October 8, 2015 On September 14, 2015, Raptor Pharmaceutical Corp. (NASDAQ: RPTP) announced top-line results of its Phase 2b trial evaluating RP103 in...
Read More Second Phase 2 clinical trial initiated for fatty liver disease with advanced fibrosis
0 Comments , in Article
Written by Peter G. Traber, M.D. on September 16, 2015 As a company, we are focused on developing a therapy for patients with non-alcoholic steatohepatitis (NASH), or fatty liver disease,...
Read More